Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus valsartan for left ventricular remodeling in ischemic heart failure
IRCT20240117060713N1Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sacubitril + valsartan and valsartan in heart failure (HF) and coronary arteriosclerosis (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Left ventricular ejection fraction, Cardiac index and 3 more. Started Feb 2024; status: completed.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20240117060713N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240117060713N1.